Clinical Trials Browser

Stomach Neoplasms

Gastric Adenocarcinoma

Stomach Neoplasms

Adenocarcinoma

Chemotherapy Effect

Pancreatic Neoplasms

Esophageal Neoplasms

Pancreatic Neoplasms

Gastric Cancer Peritoneal Metastases

Pancreatic cancer, adult, Pancreatic Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Stomach Neoplasms

Esophageal Neoplasms

Neoplasms, Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

Advanced Gastric Cancer

Gallbladder Neoplasms, Cholangiocarcinoma

Stomach Neoplasms

Stomach Neoplasms

HER2-positive Gastric Cancer

Pancreatic Adenocarcinoma

Fruquintinib

Nasopharyngeal Carcinoma, Recurrence

Cholangiocarcinoma

Stomach Neoplasms

Stomach Neoplasms

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Pancreatic Neoplasms

Advanced Non-Small Cell Lung Cancer

Stomach Neoplasms

Gastric Cancer Peritoneal Metastases

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Esophageal Neoplasms

Stomach Neoplasms

Efficacy and Safety

Stomach Neoplasms

Pancreatic Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Neoplasm Metastasis, Stomach Neoplasms

Stomach Neoplasms

Neoplasm Metastasis

Clinical Trials

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Pancreas

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

ACPC

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Remission

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

YOUNG-NEOS

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

RCTS

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT

Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Neo-ICEBOAT

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Peri-operative SLOG for Localized Pancreatic Cancer

EC-CRT-007

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma